PARLIAMENTARY WRITTEN QUESTION
(28 August 2026)

To ask the Secretary of State for Business, Innovation, Science and Trade, with reference to the press release entitled Patients to benefit from faster access to medicines as UK moves away from animal testing in science, published on 12 August 2026, if he will provide a breakdown of that funding, including the (a) name of each project, (b) recipient organisation and (c) amount awarded to each project.

Asked by:
Sarah Champion (Labour)

Innovate UK awarded funding to the following projects: VivoSphere CardioSafe Platform for Reproducible, Regulatory-Ready In Vitro Cardiotoxicity Screening (VivoSphere UK, £200,000); RITMO (BiomimX Srl, £199,991); a cardiovascular safety framework (University of Nottingham, £198,464); Integrated MPS-PBPK Platform for Non Animal Human PK Prediction (CN Bio Innovations, £180,980); chemically expanded hepatocytes for pharmacokinetic studies (University of Edinburgh, £194,563); Human Representative In Vitro Models for Ear Therapeutics (CamGene Therapeutics, £196,194); CANVAS (Biofoundry Energy, £197,092); a cardiovascular safety platform (InoCardia, £188,966); computational prediction of lipid nanoparticle pharmacokinetics (Nanograb, £199,390); and PKBridge (IOTeach, £197,500).

Answered by:
()